N/A N=337

Assessing the Impact of Calcium Channel Blockers on COGnitive Function in the Very Elderly (AI-COG)

Cognitive Ability, General · High Blood Pressure

Bottom Line

View on ClinicalTrials.gov: NCT01868165 ↗

Enrolled (actual)

337

Serious AEs

0.0%

Results posted

Sep 2019

Primary outcome: Primary: Change in Cognitive Function as Measured Using the Extended Mini Mental State Exam — 0.58 Change on a scale

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Older Adult · 80+ yrs
Sex: All
Sponsor: Imperial College London
Primary completion: Feb 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Cognitive Function as Measured Using the Extended Mini Mental State Exam	0.58	—

Summary

Older adults are at increased risk of high blood pressure and cognitive decline. High blood pressure itself also increases risk of cognitive decline. A particular type of blood pressure lowering drug (a calcium channel blocker(CCB)) may lower risk of dementia in younger adults but there is no clear evidence of it's impact in those >=80. It is important that we know whether CCB use impacts on cognitive function in this age group. This study will examine the impact of antihypertensives on change in cognitive function with a particular focus on CCBs.

Eligibility Criteria

Inclusion Criteria

Aged 80 and over Receiving pharmacological treatment for hypertension Mini Mental State Exam score >24 No other condition likely to limit life to less than one year or to prevent the taking of informed consent.

Exclusion Criteria

Aged under 80 years Not receiving pharmacological treatment for hypertension Mini Mental State Exam score <25 Diagnosed with a condition likely to limit life to less than one year or to prevent the taking of informed consent.

Presence of a sensory impairment or an existing neuropsychological deficit of sufficient severity to prevent cognitive testing.

Presence of a condition that will prevent cognitive testing, registered blind, profoundly deaf, suffering from an aphasia.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01868165). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.